Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV‐infected men in a community‐based primary care setting. Issue 11 (2nd August 2020)

• Record Type: Journal Article
• Authors: Chen, Yun‐Chi; Thio, Chloe L; Kamangar, Farin; Cox, Andrea L; Wiberg, Kjell J
• Is Part Of: Journal of viral hepatitis. Volume 27:Issue 11(2020)
• Page Start: 1202
• Page End: 1213
• Publication Date: 2020-08-02
• Subjects: HCV -- HIV -- anti‐HCV prevalence -- injection‐drug use -- men who have sex with men; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13354
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: Hepatitis C virus (HCV) infections in the United States occurred mostly among those born between 1945 and 1965. However, new infections continue to increase in recent years. To understand the changes in the prevalence and risk factors of HCV infection in different age and risk groups among men living with HIV, we performed a retrospective cross‐sectional analyses of 1948 HIV‐infected men at a multisite community health centre in urban/suburban and rural Maryland from 2003 through 2014. We used multivariate logistic regression to determine factors associated with HCV antibody (anti‐HCV) positivity and restricted cubic spline method to model trends in anti‐HCV prevalence over time. The overall anti‐HCV prevalence was 24.2%. The annual prevalence declined in the full cohort, from 38% in 2003 to 24% in 2014, and among those ≥ 40 years old. However, the annual prevalence increased initially and then stabilized in the groups of men who were younger (<40 years old) or had injection‐drug use and/or sex with men. Among the younger injection‐drug users, the prevalence rose from 33% in 2003 to 79% in 2009 and then stabilized. The independent predictors for anti‐HCV positivity differed between the men with and without injection‐drug use and between those < 40 and ≥ 40 years old. Notably, a high prevalence of anti‐HCV was observed among the younger, white injection‐drug users residing in rural areas. Thus, the HCV epidemic continued unabated among high‐risk individuals in this diverse population of HIV‐infected men. The ongoing HCV transmission among young HIV‐infected men poses a challenge en route to HCV eradication.